Pathos

Pathos is a clinical-stage biotechnology company harnessing advanced AI to revolutionize drug development. Their PathOS™ platform leverages real-world oncology and genomic data to create precision medicines through strategic partnerships.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Series D15 May, 2025
***
***
***
Series C29 Oct, 2024
***
***
***
Series B2 Mar, 2023
***
***
***
Series A1 Jul, 2021
***
***
***

*** - To view the data, please log into your account or create a new one.

Company valuation calculator

To calculate, specify one of the parameters

News related to Pathos7

Filter by
Sort by
Pathos
Aug 5, 2026 •Show on chart

Pathos AI Enters Global Licensing Agreement with Alphamab ...

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC ...

https://finance.yahoo.com/healthcare/articles/pathos-ai-enters-global-licensing-000000859.html
Pathos
Aug 5, 2026 •Show on chart

Pathos AI to license experimental breast cancer drug from ... - Reuters

New York City-based Pathos AI will pay $125 million upfront to a subsidiary ​of Alphamab Oncology for rights to an experimental ‌drug for a type of breast ...

https://www.reuters.com/legal/litigation/pathos-ai-license-experimental-breast-cancer-drug-chinas-jiangsu-alphamab-2026-08-04/
Pathos
Aug 5, 2026 •Show on chart

Pathos AI Enters Global Licensing Agreement with Alphamab ...

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC. Pathos AI, a clinical-stage AI ...

https://www.morningstar.com/news/business-wire/20260803012674/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2her3-bispecific-adc
Pathos
Aug 5, 2026 •Show on chart

Pathos AI Enters Collaboration and Co-Exclusive Licensing ...

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic....

https://www.morningstar.com/news/business-wire/20260804795138/pathos-ai-enters-collaboration-and-co-exclusive-licensing-agreement-to-advance-novel-er-protac-for-er-breast-cancer-into-the-clinic
Pathos
May 6, 2026 •Show on chart

Pathos AI Acquires Majority Stake in DeuterOncology to Advance ...

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies,...

https://markets.businessinsider.com/news/stocks/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-next-generation-met-inhibitor-identified-by-pathos-foundry-platform-1036112994
Show more (2)

Investors1

New Enterprise AssociatesNew Enterprise Associates